Unlocking Q2 Potential of Johnson & Johnson (JNJ): Exploring Wall Street Estimates for Key Metrics

Core Insights - Johnson & Johnson (JNJ) is expected to report quarterly earnings of $2.71 per share, reflecting a decline of 3.2$22.38 billion, a decrease of 12.3% year over year [1] - Analysts have revised the consensus EPS estimate down by 0.3% over the last 30 days, indicating a reassessment of initial forecasts [1] - The relationship between earnings estimate trends and short-term stock price movements is well-documented [1] Sales Projections - Analysts project 'Sales- MedTech- Total' to reach $8.21 billion, indicating a year-over-year increase of 5.4$14.18 billion, reflecting a 3.2% increase year over year [2] - 'Sales- MedTech- Orthopaedics- Trauma- WW' is estimated at $764.77 million, showing a 3.5$780.35 million, a 1.9% increase year over year [3] - 'Sales- MedTech- Orthopaedics- Hips- US' is expected to be $261.14 million, indicating a 4.5$146.40 million, reflecting a slight decline of 0.4% [3] - 'Sales- MedTech- Orthopaedics- Knees- US' is estimated at $226.07 million, a 2.3$149.67 million, indicating a 5.4% increase [3] Additional Sales Insights - 'Sales- MedTech- Orthopaedics- Trauma- US' is expected to reach $498.64 million, a 3.2$267.83 million, reflecting a 5% increase [4] - 'Sales- MedTech- Orthopaedics- Spine, Sports & Other- US' is estimated at $440.94 million, indicating a 1.8% increase [4] - Organic Sales Growth (Operational growth) is expected to be 4.9%, down from 7.5% in the same quarter last year [4] Stock Performance - Johnson & Johnson shares have increased by 2.9% over the past month, compared to a 4.3% increase in the Zacks S&P 500 composite [4]